Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock Holdings Trimmed by Wellington Management Group LLP

Wellington Management Group LLP reduced its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 35.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 705,290 shares of the medical equipment provider’s stock after selling 392,172 shares during the period. Wellington Management Group LLP’s holdings in Intuitive Surgical were worth $237,937,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ISRG. Baystate Wealth Management LLC boosted its stake in Intuitive Surgical by 150.0% in the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 45 shares during the period. MCF Advisors LLC boosted its stake in Intuitive Surgical by 108.1% in the fourth quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 40 shares during the period. Headinvest LLC acquired a new position in Intuitive Surgical in the third quarter valued at approximately $28,000. Able Wealth Management LLC acquired a new position in Intuitive Surgical in the fourth quarter valued at approximately $28,000. Finally, Stone House Investment Management LLC boosted its stake in Intuitive Surgical by 100.0% in the third quarter. Stone House Investment Management LLC now owns 100 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 50 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, Director Alan J. Levy sold 2,000 shares of the business’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total transaction of $741,400.00. Following the sale, the director now directly owns 25,319 shares of the company’s stock, valued at approximately $9,385,753.30. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Intuitive Surgical news, EVP Myriam Curet sold 5,318 shares of the business’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.66, for a total transaction of $1,971,169.88. Following the sale, the executive vice president now directly owns 298 shares of the company’s stock, valued at approximately $110,456.68. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Alan J. Levy sold 2,000 shares of the company’s stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total transaction of $741,400.00. Following the completion of the transaction, the director now directly owns 25,319 shares in the company, valued at $9,385,753.30. The disclosure for this sale can be found here. Insiders have sold a total of 17,956 shares of company stock valued at $6,927,011 in the last three months. 0.80% of the stock is currently owned by company insiders.

Intuitive Surgical Stock Performance

NASDAQ ISRG opened at $435.00 on Wednesday. The stock has a market capitalization of $154.29 billion, a P/E ratio of 78.52, a P/E/G ratio of 5.50 and a beta of 1.39. Intuitive Surgical, Inc. has a 1 year low of $254.85 and a 1 year high of $436.94. The business’s fifty day moving average is $394.44 and its two-hundred day moving average is $376.56.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The company had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. During the same quarter in the prior year, the company earned $1.00 earnings per share. The firm’s revenue was up 11.5% on a year-over-year basis. On average, research analysts forecast that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

Analyst Ratings Changes

ISRG has been the subject of several analyst reports. Jefferies Financial Group boosted their price objective on Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research report on Friday, April 19th. Robert W. Baird reduced their price objective on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research report on Friday, April 19th. Piper Sandler boosted their price objective on Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a research report on Friday, April 19th. StockNews.com downgraded Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Finally, The Goldman Sachs Group began coverage on Intuitive Surgical in a research report on Thursday, May 30th. They set a “buy” rating and a $500.00 price objective for the company. Five equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, Intuitive Surgical has an average rating of “Moderate Buy” and an average price target of $403.67.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.